EFFICACY OF ROSUVASTATIN VERSUS ATORVASTATIN IN PATIENTS WITH DIABETES: RESULTS OF A SUBGROUP ANALYSIS FROM THE POLARIS STUDY

被引：0
|
作者：
Leiter, L. A. [1 ]
Sosef, F. [2 ]
Ycas, J. [3 ]
Melezinkova, H. [4 ]
机构：
[1] Univ Toronto, St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON M5B 1W8, Canada
[2] AstraZeneca, Molndal, Sweden
[3] AstraZeneca, Wilmington, DE USA
[4] AstraZeneca, Macclesfield, Cheshire, England
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2008年 / 9卷 / 01期
关键词：
D O I：
10.1016/S1567-5688(08)70816-X
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [11] Rosuvastatin 40mg versus atorvastatin 80mg in high-risk patients with hypercholesterolaemia: Economic analysis of the POLARIS study
    Miller, PS
    Leiter, LA
    Davies, A
    Sosef, F
    VALUE IN HEALTH, 2005, 8 (06) : A103 - A103
  • [12] Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
    Berne, Christian
    Siewert-Delle, Annica
    CARDIOVASCULAR DIABETOLOGY, 2005, 4 (1)
  • [13] Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
    Christian Berne
    Annica Siewert-Delle
    Cardiovascular Diabetology, 4
  • [14] Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
    DeMicco, D
    Luo, D
    Betteridge, DJ
    Colhoun, HM
    Durrington, PN
    Hitman, GA
    Neil, HA
    Livingstone, SJ
    Fuller, JH
    CIRCULATION, 2005, 112 (17) : U907 - U907
  • [15] Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study)
    Pitt, Bertram
    Loscalzo, Joseph
    Monyak, John
    Miller, Elinor
    Raichlen, Joel
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (09): : 1239 - 1246
  • [16] Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia
    Bays, Harold E.
    Averna, Maurizio
    Majul, Claudio
    Muller-Wieland, Dirk
    De Pellegrin, Annamaria
    Giezek, Hilde
    Lee, Raymond
    Lowe, Robert S.
    Brudi, Philippe
    Triscari, Joseph
    Farnier, Michel
    AMERICAN JOURNAL OF CARDIOLOGY, 2013, 112 (12): : 1885 - 1895
  • [17] Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia - Results from the ECLIPSE study
    Faergeman, Ole
    Hill, Laurie
    Windler, Eberhard
    Wiklund, Olov
    Asmar, Roland
    Duffield, Emma
    Sosef, Froukje
    CARDIOLOGY, 2008, 111 (04) : 219 - 228
  • [18] Efficacy and tolerability of rosuvastatin 40 mg alone or in combination with ezetimibe 10 mg in patients with type 2 diabetes: results from a subgroup of the EXPLORER Study
    Ballantyne, C. M.
    Sosef, F.
    Duffield, E.
    DIABETOLOGIA, 2006, 49 : 749 - 749
  • [19] Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial
    McKenney, JM
    Jones, PH
    Adamczyk, MA
    Cain, VA
    Bryzinski, BS
    Blasetto, JW
    CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (08) : 689 - 698
  • [20] Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in high-risk patients: Results from the ECLIPSE study
    Faergeman, O.
    Sosef, F.
    Duffield, E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 580 - 580
12345